Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | Rac GTPase activating protein 1 | Starlite/ChEMBL | No references |
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0089 | 1 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.562 | 0.562 |
Schistosoma mansoni | chimerin-related rho-gtpase-activating protein | 0.0012 | 0.0016 | 0.0016 |
Echinococcus multilocularis | Rac GTPase activating protein 1 | 0.0089 | 1 | 1 |
Brugia malayi | RhoGAP domain containing protein | 0.0012 | 0.0016 | 0.0016 |
Entamoeba histolytica | hypothetical protein | 0.0012 | 0 | 0.5 |
Toxoplasma gondii | diacylglycerol kinase, putative | 0.0012 | 0 | 0.5 |
Giardia lamblia | Rho GAP, putative | 0.0077 | 0.8413 | 0.5 |
Onchocerca volvulus | 0.0012 | 0 | 0.5 | |
Brugia malayi | RhoGAP domain containing protein | 0.0077 | 0.8413 | 0.8413 |
Echinococcus granulosus | N chimaerin | 0.0012 | 0.0016 | 0.0016 |
Entamoeba histolytica | diacylglycerol kinase, putative | 0.0012 | 0 | 0.5 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.562 | 0.562 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.562 | 0.562 |
Schistosoma mansoni | chimerin-related rho-gtpase-activating protein | 0.0012 | 0.0016 | 0.0016 |
Echinococcus multilocularis | N chimaerin | 0.0012 | 0.0016 | 0.0016 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0055 | 0.562 | 0.562 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.562 | 0.562 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.562 | 0.562 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.562 | 0.562 |
Entamoeba histolytica | diacylglycerol kinase, putative | 0.0012 | 0 | 0.5 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0055 | 0.562 | 0.562 |
Onchocerca volvulus | 0.0012 | 0 | 0.5 | |
Onchocerca volvulus | 0.0012 | 0 | 0.5 | |
Loa Loa (eye worm) | RhoGAP domain-containing protein | 0.0012 | 0.0016 | 0.0016 |
Echinococcus granulosus | Rac GTPase activating protein 1 | 0.0089 | 1 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.562 | 0.562 |
Loa Loa (eye worm) | hypothetical protein | 0.0077 | 0.8413 | 0.8413 |
Schistosoma mansoni | rac gtpase activating protein | 0.0089 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | 16.1 uM | PubChem BioAssay. Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP - Primary and Confirmatory Screens. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 1 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 7.0795 uM | PubChem BioAssay. qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PubChem BioAssay. qHTS for Inhibitors of Glutaminase (GLS). (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.